Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 5/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22981209 | 0.86 | ESR1 (0.53) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL30814383 | 0.82 | ESR1 (0.52) | ESR1ESR2ABHD6 | |
| SCHEMBL23553488 | 0.82 | ESR1 (0.52) | ESR1ESR2ABHD6 | |
| SCHEMBL30814387 | 0.81 | ESR1 (0.49) | ESR1ESR2PKMABHD6 | |
| SCHEMBL19643352 | 0.77 | ESR1 (0.53) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL8177222 | 0.77 | ESR1 (0.56) | ESR1ESR2PKMABHD6 | |
| SCHEMBL507012 | 0.77 | ESR1 (0.52) | ESR1ESR2PKMABHD6HDAC6 | |
| SCHEMBL25404622 | 0.76 | ESR1 (0.52) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL7464802 | 0.76 | ESR1 (0.52) | ESR1ESR2PKMABHD6 | |
| SCHEMBL31173425 | 0.76 | ESR1 (0.56) | ESR1ESR2PKMABHD6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122741-B1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-06-06 | — | — | EP | disclosed |
| EP-3122741-B1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9951063-B2 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9951063-B2 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-3122741-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-02-01 | — | — | EP | disclosed |
| CN-106103426-A | 8 (piperazine 1 base) 1,2,3,4 tetrahydro isoquinoline derivatives | 埃科特莱茵药品有限公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015145322-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015145322-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-01 | — | — | WO | disclosed |
| US-6465485-B1 | SUCH AS 7-CYANO-2-(2-(1-(4-(2-INDOLYL)CARBOXAMIDO)CYCLO-HEXYL)ETHYL)-1,2,3,4 -TETRAHYDROISOQUINOLINE; ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-15 | — | — | US | disclosed |
| EP-0983244-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | CXCR3, CXCR1, CXCR2 | ESR1 938/4885ESR2 900/4885PKM 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.